The immune system and implantation interact in complex ways, but “immune rejection” is not a diagnosis that follows from a failed IVF transfer. Normal hormone results do not prove an immune problem either. The challenge is to separate important biology from unvalidated tests and treatments.
IVF draws attention to eggs, sperm and embryos, yet implantation also involves the endometrium and immune signaling. A good embryo grade is not a complete measure of developmental potential.
The metaphor of immunological “permission” can describe complex biology, but it is not a clinical diagnosis or a test result.
Immune adaptation in pregnancy
An embryo carries genetic material from both gametes. Pregnancy involves specialized interactions between placental, uterine and immune cells rather than a simple choice between attack and tolerance.
An immune system is not a judge of someone’s reproductive journey. Failure to implant cannot be labeled immune rejection without evidence.
Normal hormones do not identify a hidden immune cause
Repeated unsuccessful transfers warrant a review of relevant embryo, uterine and treatment factors. They do not automatically justify antibody panels, NK-cell testing or cytokine assays.
Autoimmune diseases may need their own clinical management. A thyroid antibody result or a broad claim about inflammation does not establish the cause of implantation failure or the benefit of immune treatment.
The Temptation of “Immune Therapy”
As we uncover the role of the immune system, there is a natural desire to “fix” it. However, we must be cautious. Just as we once over-emphasized embryo selection, we must not treat immune therapy as a universal “magic bullet.” The immune system is not a machine with a single “on/off” switch; it is a dynamic network. Over-treating or blindly applying immune interventions can lead to unnecessary costs, physical strain, and further failures.
From a metaphor to a testable claim
Before an add-on is offered, ask what condition it diagnoses, how reliably it does so and whether acting on the result improves live birth.
A practical discussion should include:
- Relevant medical history: Diagnose and manage established conditions rather than screening for every possible immune marker.
- Validated assessments: Ask whether a proposed test distinguishes a treatable condition and improves decisions.
- Benefits and harms: Consider costs, side effects and evidence for live birth before choosing an add-on.
Keep the assessment broad
A failed transfer is not evidence that the body withheld “permission.” Important uncertainties remain even after appropriate evaluation.
Good care weighs embryo and uterine factors together, explains uncertainty and avoids promising that immune “balancing” will open a gate to pregnancy.
This article is educational. Decisions about tests or treatment should follow a clinical assessment and evidence relevant to the individual situation.
Biology does not validate every immune treatment
ASRM finds insufficient support for many immune add-ons, while routine corticosteroids are not recommended to improve live birth in the general IVF population. Treating a diagnosed disease is a different question. ASRM immunotherapy guideline (2018).
Related reading
Uterine Environment and IVF: What Matters Beyond a Good Embryo?